Literature DB >> 7577710

Human prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitors.

C Iehlé1, S Délos, O Guirou, R Tate, J P Raynaud, P M Martin.   

Abstract

The present study describes the independent expression of the type 1 and 2 isoforms of human 5 alpha-reductase in the baculovirus-directed insect cell expression system and the selectivity of their inhibition. The catalytic properties and kinetic parameters of the recombinant isozymes were consistent with published data. The type 1 isoform displayed a neutral (range 6-8) pH optimum and the type 2 isoform an acidic (5-6) pH optimum. The type 2 isoform had higher affinity for testosterone than did the type 1 isoform (Km = 0.5 and 2.9 microM, respectively). Finasteride and turosteride were selective inhibitors of the type 2 isoform (Ki (type 2) = 7.3 and 21.7 nM compared to Ki (type 1) = 108 and 330 nM, respectively). 4-MA and the lipido-sterol extract of Serenoa repens (LSESr) markedly inhibited both isozymes (Ki (type 1) = 8.4 nM and 7.2 micrograms/ml, respectively; Ki (type 2) = 7.4 nM and 4.9 micrograms/ml, respectively). The three azasteroids were competitive inhibitors vs substrate, whereas LSESr displayed non-competitive inhibition of the type 1 isozyme and uncompetitive inhibition of the type 2 isozyme. These observations suggest that the lipid component of LSESr might be responsible for its inhibitory effect by modulating the membrane environment of 5 alpha-reductase. Partially purified recombinant 5 alpha-reductase type 1 activity was preserved by the presence of lipids indicating that lipids can exert either stimulatory or inhibitory effects on human 5 alpha-reductase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577710     DOI: 10.1016/0960-0760(95)00134-l

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  25 in total

1.  A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.

Authors:  Fatih Hizli; M Cemil Uygur
Journal:  Int Urol Nephrol       Date:  2007-01-04       Impact factor: 2.370

2.  Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.

Authors:  Michael C Byrns; Rebekka Mindnich; Ling Duan; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-12       Impact factor: 4.292

Review 3.  Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

4.  In vitro effect of D-004, a lipid extract of the fruit of the cuban royal palm (Roystonea regia), on prostate steroid 5α-reductase activity.

Authors:  L Yohani Pérez; Roberto Menéndez; Rosa Má; Rosa M González
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

Review 5.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

6.  The different reduction rate of prostate-specific antigen in dutasteride and finasteride.

Authors:  Yong Hyeuk Choi; Sung Yong Cho; In Rae Cho
Journal:  Korean J Urol       Date:  2010-10-21

Review 7.  Phytotherapy for Benign Prostatic Hyperplasia.

Authors:  Aryeh Keehn; Jacob Taylor; Franklin C Lowe
Journal:  Curr Urol Rep       Date:  2016-07       Impact factor: 3.092

8.  Semiquantitative RT-PCR method coupled to capillary electrophoresis to study 5alpha-reductase mRNA isozymes in rat ventral prostate in different androgen status.

Authors:  Jesus M Torres; José A Gómez-Capilla; Estrella Ruiz; Esperanza Ortega
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

Review 9.  Pharmacological effects of saw palmetto extract in the lower urinary tract.

Authors:  Mayumi Suzuki; Yoshihiko Ito; Tomomi Fujino; Masayuki Abe; Keizo Umegaki; Satomi Onoue; Hiroshi Noguchi; Shizuo Yamada
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

Review 10.  Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.

Authors:  Stavros Gravas; Matthias Oelke
Journal:  World J Urol       Date:  2009-12-03       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.